• OncologyTube
    • 0
      • Title
        User LIVE NOW
      • LIVE NOW
        Title
        User
        • Sign In
    • Home
    • Trending

    • Sign In

    • Audios and Videos
    • Videos
    • Audios

    • Channels

    • Browse Channels

    • Categories

    • Acute Lymphoblastic Leukemia 5637
    • Acute Myelogenous Leukemia 149
    • Bladder Cancer 49
    • Bone Metastases 1
    • Brain Cancer 16
    • Breast Cancer 121
    • Business Management 2
    • Cervical Cancer 2
    • Chronic Lymphocytic Leukemia 157
    • Chronic Myelogenous Leukemia 21
    • Colorectal Cancer 75
    • Gastrointestinal Cancer 70
    • General 246
    • Head and Neck Cancers 34
    • Hematologic Malignancies 79
    • Hodgkin Lymphoma 18
    • Immunotherapy 88
    • Kidney Cancer 364
    • Liver Cancer 11
    • Lymphoma 145
    • Melanoma and Skin Cancer 51
    • Multiple Myeloma 339
    • Myeloproliferative Disease 15
    • News 115
    • Non-Hodgkin Lymphoma 47
    • Non-Small Cell Lung Cancer 267
    • Other 111
    • Ovarian Cancer 10
    • Pancreatic Cancer 54
    • Patient Resources 27
    • Prostate Cancer 148
    • Small Cell Lung Cancer 58
    • Soft Tissue Sarcoma 9
    • Supportive Care 38
    • Testicular Cancer 2
    • Urology 6
    • Uterine Cancer 2

    • About
    • Contact
    Annual

    Annual-Meeting

    My videos
    Having a Parent, Sibling, or Child with Blood Cancer Increases One’s Own Risk

    Having a Parent, Sibling, or Child with Blood Cancer Increases One’s Own Risk

    Data from largest population study to date help identify at-risk individuals, could inform screening initiatives

    Published on: August 08, 2019

    (WASHINGTON, August 8, 2019) — New data suggest that people who have a parent, sibling, or child with blood cancer have a higher likelihood of being diagnosed with the disease. The study published online today in Blood offers the first evidence that such familial risks exist across the spectrum of hematologic malignancies.

    Age of diagnosis, whether the relative is a parent, sibling, or child, and the number of affected first-degree relatives play a defining role in the relative risk of developing certain blood cancers, according to the study.

    “This information improves our understanding of the causes of – and potential inherited predisposition to – blood cancers and should inform the identification and characterization of genetic risk factors for blood cancer, as well as how we best clinically manage patients and their relatives,” said Amit Sud, MD, PhD, of The Institute of Cancer Research, London, and the study’s lead author. “The results should also encourage conversations among families, clinicians, and patients about familial risk.”

    While earlier studies have demonstrated the increased risk of blood cancers in first-degree relatives of affected individuals, this is the largest and most comprehensive population-based evaluation to date.

    Cases with a familial link represented 4.1 percent of all blood cancer diagnoses – higher than cancers of the nervous system, kidney and pancreas, but lower than those of the breast, colorectum, and prostate, which range from 8 to 15 percent, researchers report. Highest relative risks were seen for certain Hodgkin lymphoma (HL) subtypes, lymphoplasmacytic lymphoma, and mantle cell lymphoma. Markedly elevated familial risks were also observed for polycythemia vera, myelodysplasia and essential thrombocythemia. 

    While there are currently no definitive screening initiatives for blood cancers, a 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia recognized familial disease as an essential component of diagnosing certain subsets of blood cancers and underscores the need to further examine and understand familial risk. Developing definitive screening protocols based on evidence is an emerging area of research.

    “We hope these robust data will be used to inform guidelines on genetic testing and screening. Certainly there are a number of individuals, such as those with a relative diagnosed at a young age and or with more than one affected first-degree relatives, for whom counseling, genetic testing, and surveillance may be appropriate,” Dr. Sud said. 

    The present analysis drew from 16 million people in the Swedish Family-Cancer Database, ultimately including 153,115 patients with a confirmed blood cancer and 391,131 first-degree relatives, which allowed Dr. Sud and colleagues to fully characterize familial risk across all blood cancer types. For specific blood cancers such as chronic lymphocytic leukemia (CLL), the increase in risk is dependent on the age of the affected relative; whether it is a parent, sibling, or child; and the number of affected first-degree relatives. For example, for non-Hodgkin lymphoma, HL, and CLL, the risk was higher among those who had a sibling with the disease, whereas others blood cancers were more likely to occur if a parent had been diagnosed. Generally, the familial risk was more pronounced when relatives were diagnosed at younger ages. Dr. Sud added that the analysis also has potential implications for the selection of related stem-cell donors used for the treatment of these malignancies.

    In addition to its size and long follow-up, another strength of the analysis is its use of registry data for which almost all blood cancer cases in the Swedish population had been recorded. Still, researchers say the findings may not be applicable to economically developing countries that tend to have different tumor incidence rates and potentially different environmental and genetic risk factors.

    The study was conducted as a collaboration between European research institutes: The Institute of Cancer Research in London, the German Cancer Research Centre in Heidelberg, and Lund University in Sweden.


    Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is a journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

    Contact:
    Leah Enser, American Society of Hematology
    lenser@hematology.org; 202-552-4927

    Acute Lymphoblastic Leukemia
    95 Views
    4 months ago
    Annual-Meeting
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Roswell Park Researchers Identify Immune Biomarker of Response in Patients With Advanced Liver Cancer

    Roswell Park Researchers Identify Immune Biomarker of Response in Patients With Advanced Liver Cancer

    Acute Lymphoblastic Leukemia
    72 Views
    4 months ago
    Annual-Meeting
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    TAGRISSO® (OSIMERTINIB) SIGNIFICANTLY IMPROVES OVERALL SURVIVAL IN THE PHASE III FLAURA TRIAL FOR 1ST-LINE EGFR-MUTATED NON-SMALL CELL LUNG CANCER

    TAGRISSO® (OSIMERTINIB) SIGNIFICANTLY IMPROVES OVERALL SURVIVAL IN THE PHASE III FLAURA TRIAL FOR 1ST-LINE EGFR-MUTATED NON-SMALL CELL LUNG CANCER

    Acute Lymphoblastic Leukemia
    83 Views
    4 months ago
    Annual-Meeting
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Add-On Chemo Boosts Survival in High-Risk Endometrial Cancer

    Add-On Chemo Boosts Survival in High-Risk Endometrial Cancer

    Acute Lymphoblastic Leukemia
    44 Views
    4 months ago
    Annual-Meeting
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Dermatologists can limit skin, hair, nail side effects from cancer therapy

    Dermatologists can limit skin, hair, nail side effects from cancer therapy

    Acute Lymphoblastic Leukemia
    113 Views
    4 months ago
    Annual-Meeting
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Niraparib induces responses in late-line, BRCA-negative ovarian cancer

    Niraparib induces responses in late-line, BRCA-negative ovarian cancer

    Acute Lymphoblastic Leukemia
    143 Views
    4 months ago
    Annual-Meeting
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Soricimed Announces Investigator Initiated Phase 1b Clinical trial of its Lead Drug Candidate in Late-Stage Pancreatic Cancer

    Soricimed Announces Investigator Initiated Phase 1b Clinical trial of its Lead Drug Candidate in Late-Stage Pancreatic Cancer

    Acute Lymphoblastic Leukemia
    115 Views
    4 months ago
    Annual-Meeting
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Precigen Announces First Patient Dosed in Phase 1 Study of PRGN-3005 UltraCAR-T™ in Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

    Precigen Announces First Patient Dosed in Phase 1 Study of PRGN-3005 UltraCAR-T™ in Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

    Acute Lymphoblastic Leukemia
    102 Views
    4 months ago
    Annual-Meeting
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Twitter Teaser - Pas-Arez - English Overview Lurbinectedin in Second-line SCLC
    00:00:47

    Twitter Teaser - Pas-Arez - English Overview Lurbinectedin in Second-line SCLC

    Colorectal Cancer
    6 Views
    5 months ago
    Annual-Meeting
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update—Integration of Results From T...
    00:03:16

    Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update—Integration of Results From T...

    Acute Lymphoblastic Leukemia
    767 Views
    6 months ago
    Annual-Meeting
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Updates On The FORTE Trial: 3 Arm Study, Higher Amount Of Persistent MRD At One Year In Patients Who Received A Transplant
    00:03:31

    Updates On The FORTE Trial: 3 Arm Study, Higher Amount Of Persistent MRD At One Year In Patients Who Received A Transplant

    Multiple Myeloma
    90 Views
    6 months ago
    Annual-Meeting
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Smoldering Myeloma ECOG Trial: Patients With Intermediate & High Risk MM Had An Improved Time To Progression Compared To Those Being Observed
    00:03:03

    Smoldering Myeloma ECOG Trial: Patients With Intermediate & High Risk MM Had An Improved Time To Progression Compared To Those Being Observed

    Multiple Myeloma
    214 Views
    6 months ago
    Annual-Meeting
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    IMWG Classification Of Smoldering Myeloma: Incorporates Earlier Features Of Disease, When You Have At Least 1 Cytogenetic Abnormality It Increases Progression
    00:03:57

    IMWG Classification Of Smoldering Myeloma: Incorporates Earlier Features Of Disease, When You Have At Least 1 Cytogenetic Abnormality It Increases Progression

    Multiple Myeloma
    260 Views
    6 months ago
    Annual-Meeting
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Nivolumab + Ipilimumab Combo Therapy In Patients with aHCC Results From CheckMate 040: ORR of 14& mOS of 16 Months, First Report of Efficacy & Safety of The NIVO + IPI combo in SOR-Treate...
    00:06:34

    Nivolumab + Ipilimumab Combo Therapy In Patients with aHCC Results From CheckMate 040: ORR of 14& mOS of 16 Months, First Report of Efficacy & Safety of The NIVO + IPI combo in SOR-Treate...

    Acute Lymphoblastic Leukemia
    310 Views
    6 months ago
    Annual-Meeting
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Bringing Primary Physician Back Into The Care Of Patients With Cancer: Not All Primary Care Physicians Feel Comfortable Or Would Like To Engage With Their Patients While They Are Getting ...
    00:00:00

    Bringing Primary Physician Back Into The Care Of Patients With Cancer: Not All Primary Care Physicians Feel Comfortable Or Would Like To Engage With Their Patients While They Are Getting ...

    Acute Lymphoblastic Leukemia
    120 Views
    6 months ago
    Annual-Meeting
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Need To Optimize Communication & Care Coordination: Sexual Health Is Important & Doctors Need To Ask Questions About It, Electronic Health Records Have Potential To Improve Communication
    00:01:34

    Need To Optimize Communication & Care Coordination: Sexual Health Is Important & Doctors Need To Ask Questions About It, Electronic Health Records Have Potential To Improve Communication

    Patient Resources
    78 Views
    6 months ago
    Annual-Meeting
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Updates In Myeloid Disorders: How To Calculate The Blast In Myelodysplastic Syndrome, New Treatments, Safety, & Ongoing Trials
    00:02:31

    Updates In Myeloid Disorders: How To Calculate The Blast In Myelodysplastic Syndrome, New Treatments, Safety, & Ongoing Trials

    Myeloproliferative Disease
    30 Views
    6 months ago
    Annual-Meeting
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    How To Use Drugs In Patients With Myeloid Disorders: Focusing On Azacitidine & Decitabine, When To Dose Reduce A Drug & When To Give Less Days Of The Drug
    00:02:32

    How To Use Drugs In Patients With Myeloid Disorders: Focusing On Azacitidine & Decitabine, When To Dose Reduce A Drug & When To Give Less Days Of The Drug

    Myeloproliferative Disease
    42 Views
    6 months ago
    Annual-Meeting
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Some That Image Well Do Not Respond: BRCA2 Is Associated With A Better Outcome While p53 Alterations May Have A Worse Prognosis
    00:01:09

    Some That Image Well Do Not Respond: BRCA2 Is Associated With A Better Outcome While p53 Alterations May Have A Worse Prognosis

    Prostate Cancer
    12 Views
    6 months ago
    Annual-Meeting
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    If They Are Imaging Negative, How Are They Responding: No Imaging Modality Is Perfect, 80% Use Plain Imaging Which Is Not As Sensitive As What Were Doing Now
    00:01:15

    If They Are Imaging Negative, How Are They Responding: No Imaging Modality Is Perfect, 80% Use Plain Imaging Which Is Not As Sensitive As What Were Doing Now

    Prostate Cancer
    141 Views
    6 months ago
    Annual-Meeting
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    TROPHY-u-01 Trial: A Phase II Open-Label Study Of Sacituzumab Govitecan (IMMU-132) In Patients With Advanced Urothelial Cancer
    00:01:52

    TROPHY-u-01 Trial: A Phase II Open-Label Study Of Sacituzumab Govitecan (IMMU-132) In Patients With Advanced Urothelial Cancer

    Bladder Cancer
    178 Views
    6 months ago
    Annual-Meeting
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Targeting PSMA: Patients That Have At Least One Bright Image Tend To Have A Better Chance At Responding
    00:02:03

    Targeting PSMA: Patients That Have At Least One Bright Image Tend To Have A Better Chance At Responding

    Prostate Cancer
    15 Views
    6 months ago
    Annual-Meeting
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Treatment Sequencing For Castrate Resistant M0 Disease: Looking At 3 Drugs Enzalutamide, Apalutamide, & Darolutamide, The Options Are The Challenge
    00:02:33

    Treatment Sequencing For Castrate Resistant M0 Disease: Looking At 3 Drugs Enzalutamide, Apalutamide, & Darolutamide, The Options Are The Challenge

    Prostate Cancer
    145 Views
    6 months ago
    Annual-Meeting
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    TITAN Trial: Many Options Including Chemo, Abiraterone, Enzalutamide, & Apalutamide All Showing A Benefit
    00:01:55

    TITAN Trial: Many Options Including Chemo, Abiraterone, Enzalutamide, & Apalutamide All Showing A Benefit

    Prostate Cancer
    132 Views
    6 months ago
    Annual-Meeting
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Updated Data From Phase 3 COLUMBUS Trial: Encorafenib Was The Agent Of Interest In This Study, Encorafenib Was Superior To Vemurafenib
    00:05:53

    Updated Data From Phase 3 COLUMBUS Trial: Encorafenib Was The Agent Of Interest In This Study, Encorafenib Was Superior To Vemurafenib

    Melanoma and Skin Cancer
    117 Views
    6 months ago
    Annual-Meeting
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login

      Copyright 2019 Medicus Networks, Inc.